LONG-TERM RESULTS OF TREATMENT OF ENDOMETRIAL CANCER OF IBG1-2 STAGE
https://doi.org/10.29235/1814-6023-2018-15-1-28-39
Abstract
In a retrospective study, the results of treatment of 548 patients with endometrial cancer (EС) of intermediate risk of IBG1-2 stage for 2006–2010 were evaluated. The overall, cancer-specific and disease-free 5-year survival rate was 83.7 ± 1.6, 91.2 ± 1.2, 88.4 ± 1.4 %. The best treatment results were obtained during combined treatment with the use of simple hysterectomy with bilateral salpingo-oophorectomy and adjuvant extra-beam radiation therapy. Chemotherapy did not improve the treatment results. A joint application in the treatment regimen of pelvic lymphadenectomy and adjuvant extrabeam radiation therapy on the pelvic regimen is impractical, since it does not affect the survival rate. Differences in survival rates in the regions were established at the stage of IBG1-2. Despite the fact that the methods of treatment of this stage of EC are standardized, the differences obtained can be evidence of an insufficiently effective quality of treatment in a number of regions of the Republic. In regions with the lowest survival rates, attention should be paid to the technique of operations, how adequately the extrafascial hysterectomy is performed, the length of the resected vaginal cuff, the start time, the dose and duration of radiation therapy, the size of the irradiation fields and the volume of irradiated tissues, the equipment for radiation therapy and others.
About the Authors
Sergey A. Mavrichev
N. N. Alexandrov National Cancer Centre
Belarus
Belarus
Ph. D. (Med.), Head of the Department
Lesnoy, 223040, Minsk district, Minsk region
Sergey A. Krasny
N. N. Alexandrov National Cancer Centre
Belarus
Belarus
Corresponding Member, Dr. Sc. (Med.), Professor, Deputy Director
223040, Lesnoy, Minsk district, Minsk region
References
1. Malkasian G. D. Carcinoma of the endometrium: effect of stage and grade on survival. Cancer, 1978, vol. 41, no. 3, pp. 996–1001. DOI: 10.1002/1097-0142(197803)41:33.0.CO;2-A
2. Creutzberg C. L., van Putten W. L., Koper P. C., Lybeert M. L., Jobsen J. J., Wárlám-Rodenhuis C. C., De Winter K. A., Lutgens L. C., van den Bergh A. C., van de Steen-Banasik E., Beerman H., van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentrerandomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet, 2000, vol. 355, no. 9213, pp. 1404–1411. DOI: 10.1016/s0140-6736(00)02139-5
3. Keys H. M., Roberts J. A., Brunetto V. L., Zaino R. J., Spirtos N. M., Bloss J. D., Pearlman A., Maiman M. A., Bell J. G. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecology Oncology Group study. Gynecologic Oncology, 2004, vol. 92, no. 3, pp. 744–751. DOI: 10.1016/j. ygyno.2003.11.048
4. Burke W. M., Orr J., Leitao M., Salom E., Gehrig P., Olawaiye A. B., Brewer M., Boruta D., Villella J., Herzog T., Abu Shahin F. Endometrial cancer: a review and current management: part I. SGO Clinical Practice Endometrial Cancer Working Group. Gynecologic Oncology, 2014, vol. 134, no. 2, pp. 385–392. DOI: 10.1016/j.ygyno.2014.05.018
5. Burke W. M, Orr J., Leitao M., Salom E., Gehrig P., Olawaiye A. B., Brewer M., Boruta D., Villella J., Herzog T., Abu Shahin F. Endometrial cancer: a review and current management: part II. SGO Clinical Practice Endometrial Cancer Working Group. Gynecologic Oncology, 2014, vol. 134, no. 2, pp. 393–402. DOI: 10.1016/j.ygyno.2014.06.003
6. Colombo N., Creutzberg C., Amant F., Bosse T., González-Martín A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M. R., Sessa C. ESMO-ESGO-ESTROConsensusConference on Endometrial Cancer: diagnosis, treatment and followup. International Journal of Gynecological Cancer, 2016, vol. 26, no. 1, pp. 2–30. DOI: 10.1097/IGC.0000000000000609
7. McCormick T. C., Cardenes H., Randall M. E. Early-stage endometrial cancer: is intravaginal radiation therapy alone sufficient therapy? Brachytherapy, 2002, vol. 1, no. 2, pp. 61–65. DOI: 10.1016/S1538-4721(02)00012-0
8. Lilie L. L., Mutch D. G., Rader J. S., Powell M. A., Grigsby P. W. External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer. Gynecologic Oncology, 2007, vol. 106, no. 1, pp. 215–220. DOI: 10.1016/j.ygyno.2007.03.024
Review
For citations:
Mavrichev S.A., Krasny S.A. LONG-TERM RESULTS OF TREATMENT OF ENDOMETRIAL CANCER OF IBG1-2 STAGE. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2018;15(1):28-39. (In Russ.) https://doi.org/10.29235/1814-6023-2018-15-1-28-39
Views: 535
Email this article 